Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Individuals

被引:46
作者
Lazzaretti, Rosmeri K. [1 ]
Kuhmmer, Regina [1 ]
Sprinz, Eduardo [2 ,3 ]
Polanczyk, Carisi A. [1 ,3 ]
Ribeiro, Jorge P. [1 ,3 ]
机构
[1] Hosp Clinicas Porto Alegre, Div Cardiol, BR-90035007 Porto Alegre, RS, Brazil
[2] Hosp Clinicas Porto Alegre, Div Internal Med, Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Fac Med, Dept Med, Porto Alegre, RS, Brazil
关键词
AIDS; cholesterol; nutrition; HIV-INFECTED PATIENTS; PROTEASE INHIBITOR; CHOLESTEROL; AIDS; MANAGEMENT; TRIALS; ADULTS; LIPIDS; RECOMMENDATIONS; LIPODYSTROPHY;
D O I
10.1016/j.jacc.2011.11.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to evaluate the efficacy of dietary intervention on blood lipids of human immunodeficiency virus (HIV)-1-infected patients who are started on highly active antiretroviral therapy (HAART). Background Current guidelines recommend diet as first-step intervention for HIV-1-infected individuals with HAART-related dyslipidemia, but there is no evidence from randomized trials to support this recommendation. Methods Eighty-three HIV-1-infected patients, naive from HAART, were randomly assigned to HAART with dietary intervention (diet group, n = 43) or HAART without dietary intervention (control group, n = 40) for 12 months. Diet, according to the National Cholesterol Education Program, was given every 3 months. Before and after intervention, 24-h food records and lipid profile were obtained. Data were analyzed by intention to treat, using mixed-effects models. Results Diet resulted in reduction of percentage of fat intake (from 31 +/- 7% to 21 +/- 3% of calories), while controls presented no change in percentage of fat intake. Plasma cholesterol (from 151 +/- 29 mg/dl to 190 +/- 33 mg/dl) and low-density lipoprotein cholesterol (from 85 +/- 24 mg/dl to 106 +/- 31 mg/dl) increased in the control group and were unchanged in the diet group. Plasma triglycerides were reduced by diet (from 135 +/- 67 mg/dl to 101 +/- 42 mg/dl) and increased in the control group (from 134 +/- 70 mg/dl to 160 +/- 76 mg/dl). After 1-year follow-up, 21% of patients who received diet had lipid profile compatible with dyslipidemia compared with 68% (p < 0.001) of controls. Conclusions Among HIV-1-positive individuals naive of previous treatment, diet prevents dyslipidemia associated with HAART. (Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial; NCT00429845) (J Am Coll Cardiol 2012;59:979-88) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:979 / 988
页数:10
相关论文
共 37 条
  • [1] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [2] Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia
    Barrios, A
    Blanco, F
    García-Benayas, T
    Gómez-Viera, JM
    de la Cruz, JJ
    Soriano, V
    González-Lahoz, J
    [J]. AIDS, 2002, 16 (15) : 2079 - 2081
  • [3] Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia
    Batterham, MJ
    Brown, D
    Workman, C
    [J]. AIDS, 2003, 17 (09) : 1414 - 1416
  • [4] A REVIEW OF VALIDATIONS OF DIETARY ASSESSMENT METHODS
    BLOCK, G
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 115 (04) : 492 - 505
  • [5] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [6] Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic
    Crum-Cianflone, Nancy
    Roediger, Mollie Poehlman
    Eberly, Lynn
    Headd, Maryam
    Marconi, Vincent
    Ganesan, Anuradha
    Weintrob, Amy
    Barthel, R. Vincent
    Fraser, Susan
    Agan, Brian K.
    [J]. PLOS ONE, 2010, 5 (04):
  • [7] Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
    Dubé, MP
    Stein, JH
    Aberg, JA
    Fichtenbaum, CJ
    Gerber, JG
    Tashima, KT
    Henry, WK
    Currier, JS
    Sprecher, D
    Glesby, MJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) : 613 - 627
  • [8] Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Fisac, C
    Fumero, E
    Crespo, M
    Roson, B
    Ferrer, E
    Virgili, N
    Ribera, E
    Gatell, JM
    Podzamczer, D
    [J]. AIDS, 2005, 19 (09) : 917 - 925
  • [9] Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome
    Fitch, Kathleen V.
    Anderson, Ellen J.
    Hubbard, Jane L.
    Carpenter, Sara J.
    Waddell, William R.
    Caliendo, Angela M.
    Grinspoon, Steven K.
    [J]. AIDS, 2006, 20 (14) : 1843 - 1850
  • [10] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499